Progress of research on biomarkers of diabetic kidney disease

doi:10.3877/cma.j.issn.2095-3216.2018.02.007

Abstract

Abstract:

Diabetic kidney disease (DKD) is a one of the common complications of diabetes, and is a leading cause of end-stage renal disease. Early diagnosis and disease course prediction of DKD become crucial for clinical management improvement due to the lack of effective treatment. Although proteinuria and serum creatinine are important indicators for early diagnosis and prognosis evaluation of DKD, in fact, their diagnostic efficiency is very limited. Therefore, there is an urgent need to find more efficient biomarkers in diagnosing or predicting DKD. This article reviewed recent advances in the study of biomarkers of DKD so as to provide ideas for the development of diagnostic strategies.

Key words: Diabetic kidney disease, Biomarkers, Early diagnosis, Prognosis evaluation

Bin Li, Zheyi Dong, Xianglu Rong, Xiangmei Chen. Progress of research on biomarkers of diabetic kidney disease[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2018, 07(02): 82-85.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2018.02.007

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2018/V07/I02/82

References 40

[1]	Ogurtsova K, Da Rocha Fernandes JD, Huang Y, et al. Global estimates for the prevalence of diabetes for 2015 and 2040 [J]. Diabetes Res Clin Pract, 2017, 128:40-50.
[2]	Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China [J]. N Engl J Med, 2010, 362(12):1090-1101.
[3]	Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults [J]. JAMA, 2013, 310(9):948-959.
[4]	Macisaac RJ, Ekinci EI, Jerums G. Markers of and risk factors for the development and progression of diabetic kidney disease [J]. Am J Kidney Dis, 2014, 63(Suppl 2):S39-S62.
[5]	Zhang L, Long J, Jiang W, et al. Trends in chronic kidney disease in China [J]. N Engl J Med, 2016, 375(9):905-906.
[6]	Perkins BA, Ficociello LH, Ostrander BE, et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes [J]. J Am Soc Nephrol, 2007, 18(4):1353-1361.
[7]	Perkins BA, Ficociello LH, Roshan B, et al. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria [J]. Kidney Int, 2010, 77(1):57-64.
[8]	Nauta FL, Boertien WE, Bakker SJ, et al. Glomerular and tubular damage markers are elevated in patients with diabetes [J]. Diabetes Care, 2011, 34(4):975-981.
[9]	Hara M, Yamagata K, Tomino Y, et al. Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin [J]. Diabetologia, 2012, 55(11):2913-2919.
[10]	Nielsen SE, Sugaya T, Tarnow L, et al. Tubular and glomerular injury in diabetes and the impact of ACE inhibition [J]. Diabetes Care, 2009, 32(9):1684-1688.
[11]	Pavkov ME, Weil EJ, Fufaa GD, et al. Tumor necrosis factor receptors 1 and 2 are associated with early glomerular lesions in type 2 diabetes [J]. Kidney Int, 2016, 89(1):226-234.
[12]	Wolkow PP, Niewczas MA, Perkins B, et al. Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics [J]. J Am Soc Nephrol, 2008, 19(4):789-797.
[13]	Mohamed R, Jayakumar C, Chen F, et al. Low-dose Il-17 therapy prevents and reverses diabetic nephropathy, metabolic syndrome, and associated organ fibrosis [J]. J Am Soc Nephrol, 2016, 27(3):745-765.
[14]	Christou GA, Kiortsis DN. The role of adiponectin in renal physiology and development of albuminuria [J]. J Endocrinol, 2014, 221(2):R49-R61.
[15]	Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice [J]. J Clin Invest, 2008, 118(5):1645-1656.
[16]	Von Eynatten M, Liu D, Hock C, et al. Urinary adiponectin excretion: a novel marker for vascular damage in type 2 diabetes [J]. Diabetes, 2009, 58(9):2093-2099.
[17]	Saraheimo M, Forsblom C, Thorn L, et al. Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes [J]. Diabetes Care, 2008, 31(6):1165-1169.
[18]	Panduru NM, Saraheimo M, Forsblom C, et al. Urinary adiponectin is an independent predictor of progression to end-stage renal disease in patients with type 1 diabetes and diabetic nephropathy [J]. Diabetes Care, 2015, 38(5):883-890.
[19]	Hull TD, Agarwal A. Bilirubin: a potential biomarker and therapeutic target for diabetic nephropathy [J]. Diabetes, 2014, 63(8):2613-2616.
[20]	Riphagen IJ, Deetman PE, Bakker SJ, et al. Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT [J]. Diabetes, 2014, 63(8):2845-2853.
[21]	Mashitani T, Hayashino Y, Okamura S, et al. Correlations between serum bilirubin levels and diabetic nephropathy progression among Japanese type 2 diabetic patients: a prospective cohort study [J]. Diabetes Care, 2014, 37(1):252-258.
[22]	Gohda T, Niewczas MA, Ficociello LH, et al. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes [J]. J Am Soc Nephrol, 2012, 23(3):516-524.
[23]	Niewczas MA, Gohda T, Skupien J, et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes [J]. J Am Soc Nephrol, 2012, 23(3):507-515.
[24]	Pavkov ME, Nelson RG, Knowler WC, et al. Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes [J]. Kidney Int, 2015, 87(4):812-819.
[25]	Coca SG, Nadkarni GN, Huang Y, et al. Plasma biomarkers and kidney function decline in early and established diabetic kidney disease [J]. J Am Soc Nephrol, 2017, 28(9):2786-2793.
[26]	Wong MG, Perkovic V, Woodward M, et al. Circulating bone morphogenetic protein-7 and transforming growth factor-beta1 are better predictors of renal end points in patients with type 2 diabetes mellitus [J]. Kidney Int, 2013, 83(2):278-284.
[27]	Liu JJ, Pek SLT, Ang K, et al. Plasma leucine-rich alpha-2-glycoprotein 1 predicts rapid EGFR decline and albuminuria progression in type 2 diabetes mellitus [J]. J Clin Endocrinol Metab, 2017, 102(10):3683-3691.
[28]	Xu X, Zhu X, Ma M, et al. P66shc: a novel biomarker of tubular oxidative injury in patients with diabetic nephropathy [J]. Sci Rep, 2016, 6:29302.
[29]	Bhensdadia NM, Hunt KJ, Lopes-Virella MF, et al. Urine haptoglobin levels predict early renal functional decline in patients with type 2 diabetes [J]. Kidney Int, 2013, 83(6):1136-1143.
[30]	Betz BB, Jenks SJ, Cronshaw AD, et al. Urinary peptidomics in a rodent model of diabetic nephropathy highlights epidermal growth factor as a biomarker for renal deterioration in patients with type 2 diabetes [J]. Kidney Int, 2016, 89(5):1125-1135.
[31]	Rossing K, Mischak H, Dakna M, et al. Urinary proteomics in diabetes and CKD [J]. J Am Soc Nephrol, 2008, 19(7):1283-1290.
[32]	Beermann J, Piccoli MT, Viereck J, et al. Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches [J]. Physiol Rev, 2016, 96(4):1297-1325.
[33]	Pezzolesi MG, Satake E, Mcdonnell KP, et al. Circulating TGF-beta1-regulated miRNAs and the risk of rapid progression to ESRD in type 1 diabetes [J]. Diabetes, 2015, 64(9):3285-3293.
[34]	Shao Y, Ren H, Lv C, et al. Changes of serum Mir-217 and the correlation with the severity in type 2 diabetes patients with different stages of diabetic kidney disease [J]. Endocrine, 2017, 55(1):130-138.
[35]	Tkach M, Thery C. Communication by extracellular vesicles: where we are and where we need to go [J]. Cell, 2016, 164(6):1226-1232.
[36]	De S, Kuwahara S, Hosojima M, et al. Exocytosis-mediated urinary full-length megalin excretion is linked with the pathogenesis of diabetic nephropathy [J]. Diabetes, 2017, 66(5):1391-1404.
[37]	Rossi L, Nicoletti MC, Carmosino M, et al. Urinary excretion of kidney aquaporins as possible diagnostic biomarker of diabetic nephropathy [J]. J Diabetes Res, 2017, 2017:4360357.
[38]	Barutta F, Tricarico M, Corbelli A, et al. Urinary exosomal micrornas in incipient diabetic nephropathy [J]. PLoS One, 2013, 8(11):e73798.
[39]	Jia Y, Guan M, Zheng Z, et al. MiRNAs in urine extracellular vesicles as predictors of early-stage diabetic nephropathy [J]. J Diabetes Res, 2016, 2016:7932765.
[40]	Morrison EE, Bailey MA, Dear JW. Renal extracellular vesicles: from physiology to clinical application [J]. J Physiol, 2016, 594(20):5735-5748.

Please choose a citation manager

Content to export